Purple Biotech Ltd PPBT:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/04/21 EST
4.10quote price arrow down-0.38 (-8.48%)
Volume
519,811
52 week range
2.20 - 14.40

...

Loading . . .

KEY STATS

  • Open4.45
  • Day High4.45
  • Day Low3.99
  • Prev Close4.10
  • 52 Week High14.40
  • 52 Week High Date06/29/20
  • 52 Week Low2.20
  • 52 Week Low Date03/16/20
  • Market Cap4.09M
  • Shares Out860,528.69
  • 10 Day Average Volume0.54M
  • Dividend-
  • Dividend Yield-
  • Beta2.26
  • 1 Year % Change-33.46

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Purple Biotech Ltd News

There is no recent news for this security.

Latest PPBT News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous...
Eric Rowinsky M.D.
Chairman
Itzhak Israel
Chief Executive Officer
Avraham Ben-Tzvi
General Counsel
Address
Oppenheimer 4
Rehovot
7670104
Israel